All In Biotech

NDA 018150 · Curium

Thallous Chloride Tl 201

Thallous Chloride Tl-201 · Injection

Last checked: Nov 20, 2026Latest source record: Dec 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1979

Oct 23, 1979

Approved uses

3

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

51

36 serious, 7 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 22, 2025.

Thallous Chloride Tl 201 Injection is indicated for use with planar scintigraphy or single-photon emission computed tomography (SPECT) for the following applications: Myocardial perfusion imaging in adults for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress Localization of sites of parathyroid hyperactivity pre- and post-operatively in adults with elevated serum calcium and parathyroid hormone levels Thallous Chloride Tl 201 Injection is a radioactive diagnostic drug indicated for use with planar scintigraphy or single-photon emission computed tomography (SPECT) for: Myocardial perfusion imaging in adults for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress Localization of sites of parathyroid hyperactivity pre- and post-operatively in adults with elevated serum calcium and parathyroid hormone levels ( 1 )

Mechanism: Thallous chloride Tl 201 with no carrier added accumulates in viable myocardium in a manner analogous to that of potassium. Experiments in healthy subjects using labeled microspheres have shown that the myocardial distribution of thallous chloride Tl 201 correlates with regional perfusion. In clinical studies, Thallous Chloride Tl 201 images have been found to visualize areas of infarction as “cold” or nonlabeled regions that were confirmed by electrocardiographic and enzyme changes. Regions of transient myocardial ischemia corresponding to areas perfused by coronary arteries with partial...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 23, 2004 Supplement 19 · Efficacy ReviewLetterLabel
  • Dec 16, 1993 Supplement 10 · Efficacy
  • Oct 23, 1979 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • THALLOUS CHLORIDE TL 201 · THALLOUS CHLORIDE TL-201 1mCi/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Thallous Chloride Tl-201" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • tremor8
  • dizziness7
  • dyspnoea7
  • chills6
  • hyperhidrosis6
  • asthenia5
  • hepatitis b4
  • nausea4
  • blood pressure decreased3
  • bradycardia3
  • chest pain3
  • hypotension3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20055
20071
20089
20141
20153
20161
20171
20186
20192
202021
20211

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Curium

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.